Figure 5.
Long-term OS, PFS, cumulative relapse incidence, and NRM following first autologous HSCT in MS, SSc, and CD. Data for 100-day NRM and 3-year NRM, RI, PFS, and OS for each disease were as follows: MS, 1.1% (95% CI, 0.5-2.1) and 1.5% (95% CI, 0.8-2.7), 34.4% (95% CI, 30.1-38.8), 64% (95% CI, 59.6-68.5), and 95.5% (95% CI, 0.80-2.7); SSc, 5% (95% CI, 3.7-7.7), 7.2% (95% CI, 4.7-10.4), 31.1% (95% CI, 25.5-36.7), 61.8% (95% CI, 55.9-67.6), and 80.3% (95% CI, 75.8-84.8); CD, 0.9% (95% CI, 0.1-4.7), 0.9% (95% CI, 0.1-4.7), 60.4% (95% CI, 47.7-70.9), 38.7% (95% CI, 27.2-50.1), and 96.7% (95% CI, 93-100).

Long-term OS, PFS, cumulative relapse incidence, and NRM following first autologous HSCT in MS, SSc, and CD. Data for 100-day NRM and 3-year NRM, RI, PFS, and OS for each disease were as follows: MS, 1.1% (95% CI, 0.5-2.1) and 1.5% (95% CI, 0.8-2.7), 34.4% (95% CI, 30.1-38.8), 64% (95% CI, 59.6-68.5), and 95.5% (95% CI, 0.80-2.7); SSc, 5% (95% CI, 3.7-7.7), 7.2% (95% CI, 4.7-10.4), 31.1% (95% CI, 25.5-36.7), 61.8% (95% CI, 55.9-67.6), and 80.3% (95% CI, 75.8-84.8); CD, 0.9% (95% CI, 0.1-4.7), 0.9% (95% CI, 0.1-4.7), 60.4% (95% CI, 47.7-70.9), 38.7% (95% CI, 27.2-50.1), and 96.7% (95% CI, 93-100).

Close Modal

or Create an Account

Close Modal
Close Modal